Resources

VMRA-SAT is a structured self-assessment and benchmarking tool for veterinary medicines regulatory authorities. It helps authorities review their legal mandate, organisational arrangements, regulatory processes, workforce capacity and transparency in a systematic way. 

VMRA-SAT was developed to address the need for a veterinary medicines specific tool that can help countries assess the maturity of their regulatory systems in a clear and consistent way. It is intended to complement existing WOAH support mechanisms and helping fill a recognised gap in the veterinary medicines regulatory space. 

The tool helps authorities identify what is already in place, where the main gaps are and what actions may be needed to strengthen the system over time. It provides a structured basis for reflection, priority setting and institutional development planning. 

Pilot feedback shows that the tool is valued for helping authorities identify practical improvement actions, support honest self-reflection and provide a clearer basis for planning future development. Feedback also indicates that users see additional value in being able to compare progress and also saw value in opportunities for benchmarking and shared learning in the future. 

The tool can support regulatory strengthening by helping authorities make sense of complex systems in a structured way. It can inform institutional development plans, support governance discussions, guide prioritisation and help authorities present a clearer case for reform and investment. 

No. The VMRA-SAT is a self-assessment tool. The process is led by the country itself, using its own staff and the results remain entirely with the country. There is no external judgement, ranking, or conditionality attached to the assessment. It is designed as a mirror for regulators - highlighting both strengths and gaps. 

Yes. The available evidence suggests that VMRA-SAT is useful not only for reviewing the current situation, but also for shaping future action. Follow up discussions and correspondence show that authorities use the outputs to think about realistic priorities, leadership engagement and institutional development planning. 

Yes. A common assessment framework can help support benchmarking, cooperation and regulatory learning across authorities. 

The evidence shows that some authorities may find a full self-assessment difficult if their systems are still at an early stage or if staffing and resources are limited. In these contexts, the content may still be useful as a reference point or checklist, even where a full exercise is not yet realistic. In order to address this and based on the feedback received, a new web-based preliminary self-assessment version has been created to cater for those that have resource challenges. 

Yes. Even where a full exercise may not yet be practical, the tool can still be useful as a reference point or checklist for future system development.  However, the new web-based preliminary self-assessment version should be accessible and usable by all as it is intended to be easier to use regardless of stage of development or resources. 

The tool assesses eight core functions: national regulatory system governance; registration and marketing authorisation; pharmacovigilance; market surveillance and control; licensing of establishments; regulatory inspection; laboratory testing and batch release of biological products. 

Yes. Pilot feedback highlights the importance of involving the right people across relevant functions and having enough internal coordination to gather evidence, review findings and agree priorities. Feedback also points to the value of engaging senior leadership in reviewing the outcomes. 

The VMRA-SAT assesses the regulatory functions that are critical to controlling veterinary antimicrobial use: registration and marketing authorisation (are antimicrobials properly evaluated before reaching the market?), pharmacovigilance (are adverse effects and resistance patterns monitored?), market surveillance (are products on the market what they claim to be?) and inspection (are supply chains controlled and prescription requirements enforced?). By strengthening these functions, countries are better equipped to implement their National Action Plans on AMR and meet some of their commitments under the Global Action Plan and the 2024 UN Political Declaration. 

The assessment produces a detailed maturity profile across all eight functions, identifying strengths and areas for improvement. Countries are encouraged to use this to develop an institutional development plan (IDP) that prioritises actions, sets timelines and supports resource mobilisation. The tool can be repeated periodically to track progress. 

Yes. The VMRA-SAT has been or is being piloted in a number of countries across Africa (Rwanda, Botswana, Kenya, Tanzania, Uganda, Zambia), the Americas (Mexico, Chile), Asia and Pacific (Australia, Thailand, Indonesia), and Europe (United Kingdom). These countries span a wide range of regulatory maturity levels and economic contexts. 

Across the pilot evidence, the most common challenges are the time and effort required to complete the exercise, the human resources needed, the burden of gathering and organising evidence and the need for clearer interpretation of some indicators and applying scoring consistently. 

This is one of the most consistent concerns raised in the pilot phase. Discussion with pilot countries and survey analysis both show that many users found the exercise demanding, especially when balanced against other responsibilities or when documentation was difficult to assemble. In response to this feedback, a new web based preliminary tool was developed to provide a lighter starting point. Its purpose is to help authorities carry out a similar level assessment, identify gaps and consider readiness before deciding whether to complete the full VMRA SAT exercise. 

The evidence suggests that initial training is helpful, but often not enough on its own. Users also value clearer guidance on scoring and evidence, proportionate expectations around documentation, and follow up support after workshops or introductory sessions. In response to that a manual will be produced and an accompanying website with further guidance and training. 

Yes. Pilot feedback is being reviewed and used to inform future improvements, including consideration of how the approach can be made more proportionate while keeping its core purpose intact.  That is why the web-based preliminary tool, which is simpler to use and navigate, was conceived. 

No. VMRA-SAT is intended to complement existing WOAH support mechanisms, with a specific focus on strengthening veterinary medicines regulation. 

The PVS Pathway evaluates the broad performance of a country’s Veterinary Services across all their functions. The VMRA-SAT focuses specifically on the regulation of veterinary medicinal products, providing a much more detailed, function-level diagnostic. Both the PVS and VLSP teams have confirmed that the VMRA-SAT fills a gap that their instruments do not cover to the same detail. The tools are complementary, not duplicative. 

Adoption would mean the World Assembly of Delegates formally recognises the VMRA-SAT as an official WOAH tool for supporting veterinary medicines regulatory capacity-building. This would give it institutional backing, facilitate its use in WOAH programmes, support donor engagement and position it alongside the PVS Pathway and VLSP as part of WOAH’s suite of capacity-building instruments. Adoption does not make the tool mandatory - its use remains entirely voluntary. 

VMRA-SAT can be described as a mirror for regulators, helping them reflect on what is working well, where the gaps are and what progress is needed over time.  VMRA-SAT supports veterinary medicines regulatory authorities to reflect, plan and strengthen their systems in a structured and practical way.  

A resolution is planned for the 94th General Session in May 2027. A side event at the 93rd General Session in May 2026 will introduce the tool to Delegates. No vote is being sought at the 2026 session. 

Countries interested in piloting the VMRA-SAT, undertaking a preliminary web-based assessment or receiving a virtual demonstration can contact the project team at request@vmra-sat.org. There is no cost to participate as a pilot country. 

The development of the tool was funded by the Gates Foundation and developed by the UK Veterinary Medicines Directorate (UK VMD). 

Visit the VMRA-SAT website at www.vmra-sat.org, or contact the project team at feedback@vmra-sat.org.